vs
Prestige Consumer Healthcare Inc.（PBH）とWaystar Holding Corp.（WAY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Waystar Holding Corp.の直近四半期売上が大きい（$303.5M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.1倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 6.6%、差は9.9%）。Waystar Holding Corp.の前年同期比売上増加率が高い（24.3% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $57.2M）。過去8四半期でWaystar Holding Corp.の売上複合成長率が高い（16.2% vs 1.2%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
Waystar Holding Corpは、医療向け決済および収益サイクル管理ソリューションの大手プロバイダーです。米国全土の医療機関、医療システム、保険者を対象に、請求処理、保険金請求手続き、患者支払いの効率化ツールを提供し、医療組織の事務負担削減と財務パフォーマンス向上を支援しています。
PBH vs WAY — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $303.5M |
| 純利益 | $46.7M | $20.0M |
| 粗利率 | 55.5% | — |
| 営業利益率 | 29.1% | 19.4% |
| 純利益率 | 16.5% | 6.6% |
| 売上前年比 | -2.4% | 24.3% |
| 純利益前年比 | -23.5% | 4.8% |
| EPS（希薄化後） | $0.97 | $0.10 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $283.4M | $303.5M | ||
| Q3 25 | $274.1M | $268.7M | ||
| Q2 25 | $249.5M | $270.7M | ||
| Q1 25 | $296.5M | $256.4M | ||
| Q4 24 | $290.3M | $244.1M | ||
| Q3 24 | $283.8M | $240.1M | ||
| Q2 24 | $267.1M | $234.5M | ||
| Q1 24 | $277.0M | $224.8M |
| Q4 25 | $46.7M | $20.0M | ||
| Q3 25 | $42.2M | $30.6M | ||
| Q2 25 | $47.5M | $32.2M | ||
| Q1 25 | $50.1M | $29.3M | ||
| Q4 24 | $61.0M | $19.1M | ||
| Q3 24 | $54.4M | $5.4M | ||
| Q2 24 | $49.1M | $-27.7M | ||
| Q1 24 | $49.5M | $-15.9M |
| Q4 25 | 55.5% | — | ||
| Q3 25 | 55.3% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 55.5% | — | ||
| Q2 24 | 54.7% | — | ||
| Q1 24 | 54.8% | — |
| Q4 25 | 29.1% | 19.4% | ||
| Q3 25 | 29.1% | 22.4% | ||
| Q2 25 | 28.8% | 24.0% | ||
| Q1 25 | 29.8% | 25.4% | ||
| Q4 24 | 31.7% | 21.8% | ||
| Q3 24 | 29.7% | 11.3% | ||
| Q2 24 | 27.0% | 3.5% | ||
| Q1 24 | 29.7% | 15.7% |
| Q4 25 | 16.5% | 6.6% | ||
| Q3 25 | 15.4% | 11.4% | ||
| Q2 25 | 19.0% | 11.9% | ||
| Q1 25 | 16.9% | 11.4% | ||
| Q4 24 | 21.0% | 7.8% | ||
| Q3 24 | 19.2% | 2.3% | ||
| Q2 24 | 18.4% | -11.8% | ||
| Q1 24 | 17.9% | -7.1% |
| Q4 25 | $0.97 | $0.10 | ||
| Q3 25 | $0.86 | $0.17 | ||
| Q2 25 | $0.95 | $0.18 | ||
| Q1 25 | $1.00 | $0.16 | ||
| Q4 24 | $1.22 | $0.18 | ||
| Q3 24 | $1.09 | $0.03 | ||
| Q2 24 | $0.98 | $-0.21 | ||
| Q1 24 | $0.98 | $-0.13 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $61.4M |
| 総負債低いほど良い | $1.0B | $1.5B |
| 株主資本純資産 | $1.8B | $3.9B |
| 総資産 | $3.5B | $5.8B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | 0.38× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.4M | $61.4M | ||
| Q3 25 | $119.1M | $421.1M | ||
| Q2 25 | $139.5M | $290.3M | ||
| Q1 25 | $97.9M | $224.0M | ||
| Q4 24 | $50.9M | $182.1M | ||
| Q3 24 | $51.5M | $127.1M | ||
| Q2 24 | $34.3M | $68.4M | ||
| Q1 24 | $46.5M | $57.3M |
| Q4 25 | $1.0B | $1.5B | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | $1.2B | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $1.8B | $3.9B | ||
| Q3 25 | $1.8B | $3.2B | ||
| Q2 25 | $1.9B | $3.2B | ||
| Q1 25 | $1.8B | $3.1B | ||
| Q4 24 | $1.8B | $3.1B | ||
| Q3 24 | $1.7B | $3.1B | ||
| Q2 24 | $1.7B | $2.9B | ||
| Q1 24 | $1.7B | $2.0B |
| Q4 25 | $3.5B | $5.8B | ||
| Q3 25 | $3.4B | $4.7B | ||
| Q2 25 | $3.4B | $4.7B | ||
| Q1 25 | $3.4B | $4.6B | ||
| Q4 24 | $3.3B | $4.6B | ||
| Q3 24 | $3.3B | $4.5B | ||
| Q2 24 | $3.3B | $4.6B | ||
| Q1 24 | $3.3B | — |
| Q4 25 | 0.56× | 0.38× | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | 0.40× | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $66.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | $57.2M |
| FCFマージンFCF / 売上 | 26.6% | 18.9% |
| 設備投資強度設備投資 / 売上 | 1.1% | 3.1% |
| キャッシュ転換率営業CF / 純利益 | 1.68× | 3.33× |
| 直近12ヶ月FCF直近4四半期 | $267.2M | $283.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.3M | $66.6M | ||
| Q3 25 | $57.5M | $82.0M | ||
| Q2 25 | $79.0M | $96.8M | ||
| Q1 25 | $61.8M | $64.2M | ||
| Q4 24 | $65.1M | — | ||
| Q3 24 | $69.8M | $78.8M | ||
| Q2 24 | $54.8M | $15.4M | ||
| Q1 24 | $66.9M | $10.7M |
| Q4 25 | $75.3M | $57.2M | ||
| Q3 25 | $55.4M | $76.2M | ||
| Q2 25 | $78.2M | $91.0M | ||
| Q1 25 | $58.4M | $58.8M | ||
| Q4 24 | $63.5M | — | ||
| Q3 24 | $67.8M | $70.2M | ||
| Q2 24 | $53.6M | $8.6M | ||
| Q1 24 | $63.8M | $5.2M |
| Q4 25 | 26.6% | 18.9% | ||
| Q3 25 | 20.2% | 28.3% | ||
| Q2 25 | 31.3% | 33.6% | ||
| Q1 25 | 19.7% | 22.9% | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 23.9% | 29.2% | ||
| Q2 24 | 20.1% | 3.7% | ||
| Q1 24 | 23.0% | 2.3% |
| Q4 25 | 1.1% | 3.1% | ||
| Q3 25 | 0.8% | 2.2% | ||
| Q2 25 | 0.3% | 2.1% | ||
| Q1 25 | 1.2% | 2.1% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.7% | 3.6% | ||
| Q2 24 | 0.4% | 2.9% | ||
| Q1 24 | 1.1% | 2.5% |
| Q4 25 | 1.68× | 3.33× | ||
| Q3 25 | 1.36× | 2.68× | ||
| Q2 25 | 1.66× | 3.01× | ||
| Q1 25 | 1.23× | 2.20× | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | 14.56× | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | 1.35× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
WAY
| Subscription And Circulation | $167.8M | 55% |
| Volume Based Revenue | $134.2M | 44% |
| Implementation Services And Other Revenue | $1.5M | 1% |
